These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 25425260)

  • 1. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.
    Nakamura H; Fang J; Maeda H
    Expert Opin Drug Deliv; 2015 Jan; 12(1):53-64. PubMed ID: 25425260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS.
    Fang J; Sawa T; Maeda H
    Adv Exp Med Biol; 2003; 519():29-49. PubMed ID: 12675206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo.
    Maeda H; Nakamura H; Fang J
    Adv Drug Deliv Rev; 2013 Jan; 65(1):71-9. PubMed ID: 23088862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects.
    Maeda H
    Bioconjug Chem; 2010 May; 21(5):797-802. PubMed ID: 20397686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
    Greish K
    J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic Therapy--Problems, Solutions, and Prospects.
    Maeda H; Tsukigawa K; Fang J
    Microcirculation; 2016 Apr; 23(3):173-82. PubMed ID: 26237291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.
    Fang J; Nakamura H; Maeda H
    Adv Drug Deliv Rev; 2011 Mar; 63(3):136-51. PubMed ID: 20441782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity.
    Maeda H
    Adv Drug Deliv Rev; 2015 Aug; 91():3-6. PubMed ID: 25579058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor delivery of macromolecular drugs based on the EPR effect.
    Torchilin V
    Adv Drug Deliv Rev; 2011 Mar; 63(3):131-5. PubMed ID: 20304019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
    Maeda H; Bharate GY; Daruwalla J
    Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting.
    Maeda H
    Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(3):53-71. PubMed ID: 22450535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer drug delivery: considerations in the rational design of nanosized bioconjugates.
    Kobayashi H; Turkbey B; Watanabe R; Choyke PL
    Bioconjug Chem; 2014 Dec; 25(12):2093-100. PubMed ID: 25385142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting.
    Greish K
    Methods Mol Biol; 2010; 624():25-37. PubMed ID: 20217587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines.
    Islam W; Fang J; Imamura T; Etrych T; Subr V; Ulbrich K; Maeda H
    Mol Cancer Ther; 2018 Dec; 17(12):2643-2653. PubMed ID: 30232144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers.
    Fang J; Islam W; Maeda H
    Adv Drug Deliv Rev; 2020; 157():142-160. PubMed ID: 32553783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
    Taurin S; Nehoff H; Greish K
    J Control Release; 2012 Dec; 164(3):265-75. PubMed ID: 22800576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
    Maeda H; Wu J; Sawa T; Matsumura Y; Hori K
    J Control Release; 2000 Mar; 65(1-2):271-84. PubMed ID: 10699287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The link between infection and cancer: tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect.
    Maeda H
    Cancer Sci; 2013 Jul; 104(7):779-89. PubMed ID: 23495730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micro/nano-bubble-assisted ultrasound to enhance the EPR effect and potential theranostic applications.
    Duan L; Yang L; Jin J; Yang F; Liu D; Hu K; Wang Q; Yue Y; Gu N
    Theranostics; 2020; 10(2):462-483. PubMed ID: 31903132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
    Danhier F
    J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.